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Abstract
Context—Patients with symptomatic atherosclerotic internal carotid artery occlusion (AICAO)
and hemodynamic cerebral ischemia are at high risk for subsequent stroke when treated medically.
Objective—Test the hypothesis that extracranial-intracranial (EC-IC) bypass surgery, added to
best medical therapy, reduces subsequent ipsilateral ischemic stroke in patients with recently
symptomatic AICAO and hemodynamic cerebral ischemia.
Design—Parallel group, randomized, open-label, blinded-adjudication clinical treatment trial
conducted from 2002–2010.
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Setting—49 clinical centers and 18 positron emission tomography (PET) centers in the United
States and Canada. The majority were academic medical centers.
Participants—Arteriographically-confirmed AICAO causing hemispheric symptoms within 120
days and hemodynamic cerebral ischemia identified by ipsilateral increased oxygen extraction
fraction measured by PET. 195 were randomized: 97 to surgery and 98 to no surgery. Follow-up
for the primary endpoint until occurrence, 2 years, or end of trial was 99% complete. No
participant withdrew because of adverse events.
Interventions—Anastomosis of superficial temporal artery branch to a middle cerebral artery
cortical branch for the surgical group. Anti-thrombotic therapy and risk factor intervention were
recommended for all.
Main Outcome Measure—For all participants who were assigned to surgery and received
surgery, the combination of (1) all stroke and death from surgery through 30 days post surgery and
(2) ipsilateral ischemic stroke within 2 years of randomization. For the nonsurgical group and
participants assigned to surgery who did not receive surgery was the combination of (1) all stroke
and death from randomization to randomization plus 30 days and (2) ipsilateral ischemic stroke
within two years of randomization.
Results—The trial was terminated early for futility. Two-year rates for the primary endpoint
were 21.0% (95% CI, 12.8% to 29.2%; 20 events) for the surgical group and 22.7% (95% CI,
13.9% to 31.6%; 20 events) for the nonsurgical group (p=0.78, z-test); difference = 1.7% (95% CI,
−10.4% to 13.8%). Thirty-day rates for ipsilateral ischemic stroke were 14.3% (14/97) in the
surgical group and 2.0% (2/98) in the nonsurgical group; difference = (95% CI, 4.9% to 19.9%)
Conclusions—Among participants with recently symptomatic AICAO and hemodynamic
cerebral ischemia, EC-IC bypass surgery plus medical therapy compared to medical therapy alone
did not reduce the risk of recurrent ipsilateral ischemic stroke at 2 years.
INTRODUCTION
Atherosclerotic internal carotid artery occlusion (AICAO) causes approximately 10% of
transient ischemic attacks (TIAs) and 15–25% of ischemic strokes in the carotid territory.1,2
The 2-year risk of subsequent ipsilateral ischemic stroke on medical therapy is 10–15%.1–3
Extracranial-intracranial (EC-IC) arterial bypass surgery was developed to prevent
subsequent stroke by improving hemodynamics distal to the occluded artery.4 In 1985, a
randomized trial demonstrated no benefit of this surgery in 808 patients with symptomatic
carotid artery occlusion.5 This trial was criticized for failing to identify the subgroup of
patients with hemodynamic cerebral ischemia due to poor collateral circulation for whom
surgical revascularization might be of greatest benefit.6–8 Subsequent advances in
neuroimaging have made it possible to identify those with hemodynamic cerebral ischemia
who are at high risk for subsequent stroke when treated medically.3,9–11 We conducted the
Carotid Occlusion Surgery Study (COSS) to determine if EC-IC bypass surgery, added to
best medical therapy, reduces subsequent ipsilateral ischemic stroke at 2 years in patients
with recently symptomatic AICAO and hemodynamic cerebral ischemia identified by
positron emission tomography (PET) measurements of oxygen extraction fraction (OEF).
METHODS
COSS was a parallel group, 1:1 randomized, open-label, blinded-adjudication treatment trial
conducted at 49 clinical centers and 18 PET centers in the United States and Canada.
Personnel at the clinical coordinating center, including the principal investigator and project
manager, were blinded to treatment assignment and to outcome, except that persons who
paid local sites or processed post-operative PET scans knew treatment assignment. Protocol
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amendments were made during the trial with approval of the data, safety and monitoring
board (DSMB) appointed by the National Institute of Neurological Diseases and Stroke
(NINDS) (eMethods 1). This description is based on the final protocol (copy available on
request).
Potential participants were identified by monitoring vascular imaging studies and soliciting
referrals from physicians. Primary clinical inclusion criteria were (1) vascular imaging
demonstrating complete occlusion of an internal carotid artery and (2) TIA or ischemic
stroke in the hemispheric territory of an occluded internal carotid artery within 120 days.
(See eMethods 2 for full listing of clinical eligibility criteria.) Participants who fulfilled
initial clinical eligibility criteria provided written informed consent according to local IRB
regulations and proceeded to PET. Participants underwent PET at COSS-approved PET sites
(United States Food and Drug Administration Investigational New Drug Application
#62,657). Forty second emission images were compiled from 2-sec dynamic images
obtained following intravenous administration of 75 mCi H215O and following inhalation of
100 mCi O15O. Ipsilateral-to-contralateral ratios of mean regional carotid territory OEF
were calculated at Washington University from a quotient image of O15O / H215O PET
counts.11 A ratio >1.130 was required. Intra-arterial catheter arteriography documenting (1)
occlusion of the symptomatic internal carotid artery and (2) intracranial and extracranial
arteries suitable for anastomosis was also required.
Baseline clinical evaluation was performed prior to PET. Data on race/ethnicity in fixed
categories were collected according to National Institutes of Health clinical trial
requirements. Self-reporting or self-identification was the preferred method for collecting
data on ethnicity and race. Respondents were offered the option of selecting one or more
racial designations.
1:1 randomization sequences using permuted blocks with stratification for clinical site and
to insure comparable numbers with contralateral carotid stenosis in each group were
generated using the SAS uniform random number generator (RANUNI). Sequences for each
clinical site were loaded into a secure part of the COSS SQL server database. When a local
investigator received notification of PET eligibility and entered the information from the
Initial Eligibility and Arteriography forms, treatment assignment was obtainable from the
COSS website.
Surgical intervention
Surgical intervention was microsurgical end-to-side anastomosis of a superficial temporal
artery branch to a cortical branch of the middle cerebral artery. If the superficial temporal
branch was unsuitable, the occipital artery could be used. Neurosurgeons were certified by
(1) attendance at a 2-day training workshop with videotaped instruction and surgical practice
of microvascular anastomosis, (2) demonstration of ≥ 80% graft patency and ≤10% stroke
and death rate at 1 month in at least 10 consecutive previous EC-IC bypass surgeries, or (3)
some with fewer than 10 previous cases received a provisional certification to perform EC-
IC bypass on a participant enrolled in COSS under the supervision of the neurosurgical
principal investigator or designate.
Both treatment groups were prohibited from undergoing any additional or subsequent
surgical procedure that might alter cerebral hemodynamics or affect stroke risk, except
carotid endarterectomy for development of symptomatic contralateral carotid stenosis.
For participants in the surgical group, preoperative and postoperative antithrombotic
treatment was determined by the COSS neurosurgeon until they were returned to the
antithrombotic treatment preferred by their physicians. Participants in the nonsurgical group
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continued to receive the antithrombotic treatment preferred by their physicians. Target goals
for risk factor control were 130/85 mm Hg for blood pressure, 100 mg/dL for low density
lipoprotein cholesterol, 150 mg/dL for triglycerides, and 7% for hemoglobin A1C.
Follow up and outcome measures
The first follow-up visit was 30–35 days after randomization. Surgical participants received
a repeat PET scan 30–60 days postoperatively. Subsequent follow-up visits were at 3-month
intervals until 24 months or the end of the trial. Each follow-up examination included (1)
history and examination to identify new stroke performed by an investigator other than the
operating neurosurgeon, (2) recording current medications by class, (3) National Institutes of
Health Stroke Scale (NIHSS), modified Barthel Index, Rankin Scale, and Stroke Specific
Quality of Life (SSQoL) assessment 14–18, (4) monitoring of risk factors, and (5) Doppler
examination to assess graft patency for the surgical group. Telephone follow-up was
permitted if an in-person visit was impossible.
The primary endpoint for all participants randomized to the surgical group who received
surgery was the combination of (1) all stroke and death from surgery through 30 days post-
surgery and (2) ipsilateral ischemic stroke within 2 years of randomization. The primary
endpoint in the nonsurgical group and for those randomized to the surgical group who did
not receive surgery was the combination of (1) all stroke and death from randomization to
randomization plus 30 days and (2) ipsilateral ischemic stroke within two years of
randomization. Thus, those randomized to surgery who never underwent surgery were still
analyzed in the surgical group but the 30 day period to count all stroke and death for the
primary endpoint began at randomization, not at surgery. Ipsilateral ischemic stroke was
defined as the clinical diagnosis of a focal neurological deficit due to cerebral ischemia
clinically localizable within the territory of the symptomatic occluded internal carotid artery
that lasted for more than 24 hours.
Secondary endpoints were all stroke, disabling stroke, fatal stroke, death, NIHSS, modified
Barthel Index, Rankin Scale, and SS-QoL.14–18 The combination of any stroke or death was
added as a post hoc endpoint. All stroke was defined as the clinical diagnosis of a focal
deficit due to ischemia or hemorrhage clinically localizable to the brain lasting more than 24
hours. Fatal stroke led directly to the participant’s death within 30 days of occurrence.
Disabling stroke was defined as a modified Barthel Index of <12/20 at the first scheduled
return visit more than 3 months after the stroke occurred.
All participants and their families were urged to contact the local study coordinator for any
event that might be a stroke or in the event of death. The local site sent copies of all brain
images and arteriography obtained for clinical purposes and any other relevant information
to the statistical data and management center within 1 week. A summary that contained no
information to identify treatment group was prepared for 2 members of the adjudication
committee. If they disagreed, the summary was sent to a third adjudicator. If the third
adjudicator did not agree with either of the first 2, there was a consensus vote among all 3.
All stroke endpoints determined by the adjudication committee were classified into stroke
subtypes according to the TOAST criteria.19
A local safety monitor reviewed monthly summary reports of all adverse events by blinded
treatment assignment. NINDS appointed a DSMB that met at regular intervals.
Sample size calculation and data analysis
Sample size and power calculations assumed that the true primary outcome rates would be
40% in the nonsurgical group and 24% in the surgical group The eligibility criteria for
COSS were selected based on our 1992–1997 prospective study of patients with
Powers et al. Page 4













symptomatic AICAO to match a high risk subgroup with hemispheric symptoms within 120
days and a specific OEF threshold who had an overall rate of ipsilateral stroke at 2 years of
40% on medical therapy.3,20 Surgical morbidity and mortality were assumed to be 12% as in
the EC-IC Bypass Trial and the 2-year post operative ipsilateral stroke rate was assumed be
12%, as it was for persons with normal OEF in our previous study.3,5 For a 5% 2-sided test
to have 90% power to detect this difference, 354 participants (177 per group) were required
(nQuery Advisor Version 4, Statistical Solutions, Saugus, MA), To account for death from
nonstroke causes, the sample size was increased by 5% to 372.
Baseline characteristics were compared using generalized Fisher exact tests for categorical
variables and Wilcoxon Rank Sum tests for continuous variables. For the primary endpoint,
rates were based on product limit estimates of 2-year rates and their standard errors.
Participants were censored at their last follow-up visit. We did not impute values for
participants who were not followed for the full 2 years. The test statistic was calculated as
the difference in estimated rates divided by the standard error of that difference. The 2-sided
z-statistic was compared to a standard unit normal distribution. All randomized participants
were analyzed in the treatment group to which they were initially randomized (intention-to-
treat principle). Secondary endpoints of any stroke, fatal stroke, disabling stroke, death and
any stroke or death were analyzed using the same methods. The Barthel score was
dichotomized as 19–20 versus ≤18, using a scale of 1–20. The Rankin score was
dichotomized in 2 ways: 0–1 versus 2–6 and 0–2 versus 3–6. These are standard
dichotomizations used in stroke clinical trials. 21–23 For dichotomized outcomes, differences
between treatments were compared using Fisher exact tests. Summary SS-QoL scores were
compared using a t-test. An on-treatment analysis was performed by removing participants
assigned to the surgical group who never underwent surgery and censoring on the day of
surgery participants assigned to the nonsurgical group who underwent EC-IC bypass
surgery.
The Lan and Demets method with the O’Brien-Fleming type spending function was used for
interim analyses for efficacy assuming 2-sided 5% level test.24 A futility analysis was
performed at each interim analysis for efficacy. Thresholds for futility were computed in a
manner similar to that used for interim stopping for efficacy with a newly developed method
approved by the DSMB that controls the overall probability of a type II error at no more
than 15% level, slightly more liberal than the 10% used for the primary efficacy outcome.25
This method allows the trial to stop early for futility with larger conditional power than more
conventionally used and subjectively determined fixed thresholds of 10–15%.25 Conditional
power was computed for 3 alternatives: for the null hypothesis, for the currently observed
rates, and for the original design effect size. The conditional power applied to prespecified
futility thresholds was that based on the assumption of the original design effect size.
Futility analyses included only those participants who had completed the 2-year follow-up to
allow for the expected early perioperative stroke rate in the surgical group to be
counterbalanced by longer term reductions.
Early trial termination
The second interim analysis was conducted when 194 participants had been randomized.
The futility analysis included 139 participants who had completed 2 year follow-up: 16
primary endpoints in 74 surgical group patients and 11 primary endpoints in 65 nonsurgical
group patients. Conditional power based on the assumption of the original design effect size
was 29%, which crossed the pre-specified futility boundary of 35%. The interim analysis for
efficacy showed a between group difference in favor of the nonsurgical group of 5.0% (95%
CI −12.5% to 11.5%). The DSMB considered redesigning the trial to detect a smaller
absolute difference of 10% in favor of surgery. This would have required increasing the
overall sample size from 372 to 986 to achieve 80% power. The DSMB recommended
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stopping the trial citing (1) the prespecified statistical boundary for declaring futility had
been crossed using the design effect size and (2) given the unexpected relatively low rate of
observed primary endpoints in the nonsurgical group, a clinically meaningful difference in
favor of surgery would not be detectable without a substantial increase in sample size which
was not feasible. The study was terminated on June 24, 2010.
In December 2010, the DSMB was notified of errors in the interim analysis program. One
patient in the nonsurgical group with a vertebrobasilar stroke occurring after 30 days had
been erroneously included in the efficacy analysis. Three additional primary endpoints in the
nonsurgical group had not been included in the futility analysis. These had been adjudicated
as primary endpoints by the adjudication committee but the computer program for the earlier
analysis was not properly written with the correct event codes (2 were fatal strokes and 1
was an ipsilateral stroke occurring after a non-primary endpoint non-ipsilateral stroke). The
conditional power recomputed based on the accurate data was 1% for the null hypothesis,
2% for the currently observed rates, and 50% for the original design effect size. The
conditional power for the original design effect size did not cross the pre-specified futility
boundary of 35%. Nevertheless, the trial remained closed. The analyses presented here
based on a closure date of June 24, 2010 include all 195 participants randomized by that date
and all endpoints as of that date, including the 3 not included in the original futility analysis.
RESULTS
Between June 2002 and June 2010, 195 participants were randomized: 97 to the surgical
group and 98 to the nonsurgical group (Figure 1). Comparison of 24 baseline variables
produced 1 difference at the p<.05 level in systolic blood pressure (Table 1). Follow-up for
the primary endpoint until occurrence, 2 years, or the end of the trial was 99% complete
(Figure 1). Median follow-up for the surgical group was 723 days (interquartile range [IQR],
288 – 730) and for the nonsurgical group was 722 days (IQR, 271 – 730). At last follow-up
visit, risk factor control was similar in both groups (Table 2). Forty-three of the last
available 3-month visits were by telephone, for which there were no measurements of risk
factor control.
All primary endpoints were ipsilateral ischemic strokes, 20 in each group. In the surgical
group, 19 were due to large artery atherosclerosis and 1 was undetermined. In the
nonsurgical group, 16 were due to large artery atherosclerosis, 3 were undetermined, and 1
was due to small artery occlusion (lacune). For the intention-to-treat analysis of the primary
endpoint, the 2-year rates were 21.0% (95% CI, 12.8%, 29.2%) for the surgical group and
22.7% (95% CI, 13.9%, 31.6%) for the nonsurgical group (p=0.78, z-test); difference =
1.7% (95% CI, −10.4%, 13.8%). (Table 3, Figure 2). The confidence interval of the
difference excludes the original design effect size of 16% in favor of surgery. Given the data
at termination, and if the true 2-year rate in the surgical group is 21.0%, then the true rate in
the nonsurgical group would need to be more than 30% for the conditional power to exceed
20%. This is at the extreme of the 95% confidence interval of 31.6% for the rates at
termination. Similarly, given the data at termination and if the true 2-year rate in the
nonsurgical group is 22.7%, the true rate in remaining patients in the surgical group would
need to be less than 14% for the conditional power to exceed 20%. This is less than the
perioperative rate of 15% observed at termination (see below).
At 30 days, the rates of ipsilateral ischemic stroke were 14.3% (14/97) in the surgical group
and 2.0% (2/98) in the nonsurgical group, difference = 12.4% (95% CI, 4.9%, 19.9%). For
the intention-to-treat analyses of the secondary endpoints, there were no significant
differences at the .05 level (Table 3).
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Four participants randomized to the surgical group did not undergo surgery (Figure 1). One
had an ipsilateral ischemic stroke (primary endpoint) 9 months after randomization. Three
participants randomized to the nonsurgical group underwent ipsilateral EC-IC bypass
(Figure 1). One had an early postoperative ipsilateral ischemic stroke (primary endpoint).
For the on-treatment analysis, the 2-year estimates for the primary endpoint were 20.8%
(95% CI, 12.4%, 29.1%) for the surgical group and 22.3% (95% CI, 13.3%, 31.2%) for the
nonsurgical group (p=.81); difference = 2.0% (95% CI, −10.7%, 13.7%).
Other than crossovers, there were 3 surgical treatment protocol violations in the surgical
group (1 ipsilateral common carotid stent, 2 asymptomatic carotid endarterectomies) and 1
in the nonsurgical group (contralateral asymptomatic carotid endarterectomy). One
additional participant in the nonsurgical group underwent a contralateral carotid
endarterectomy for symptomatic carotid stenosis as permitted by the protocol. Central
arteriographic eligibility review of 191 studies (4 missing) revealed that 2 were not catheter
arteriograms and 3 were not atherosclerotic occlusions.
Ninety-three participants in the surgical group underwent surgery a median of 6 days (IQR,
1 to 13) after randomization. No strokes occurred within this period. Within 30 days
postoperatively, 14/93 (15%) experienced a stroke (all ipsilateral ischemic). Surgery was
performed by 30 different surgeons. The surgical certification method was not significantly
associated with 30 day postoperative stroke (chi-square Yates corrected .196, p= .91).
Serious adverse events occurred in 12 additional participants within the 30 day postoperative
period: 4 TIAs, 2 epidural/subdural hematomas, 2 seizures, 1 myocardial infarction, 1
respiratory disorder, 1 hypotension, and 1 wound infection. In the nonsurgical group, the
only serious adverse events within 30 days of randomization were 2 primary endpoint
ipsilateral ischemic strokes. Graft patency was 98% at 30 days (88/90 with data) and 96% at
last-follow-up (86/90). The mean OEF ratio in the surgical group improved from 1.258 at
baseline to 1.109 at the 30–60 day postoperative repeat PET scan (87 with data).
COMMENT
In spite of excellent graft patency and improved cerebral hemodynamics in the surgical
group, EC-IC bypass surgery failed to provide an overall benefit on 2-year stroke
recurrence. The 2-year primary endpoint rate of 21% in the surgical group was very close to
the rate of 24% projected from historical data. The 30-day postoperative morbidity and
mortality of 15% was not statistically significantly different from the rate of 12% (81/663)
from the EC-IC Bypass Trial (p=0.44, Chi-square).5 After the 30-day postoperative period,
the rate of recurrent stroke for the remainder of the 2-year follow-up period was 6%, half of
the 12% rate projected. In contrast, the 2-year primary endpoint rate of 23% in the
nonsurgical group was much lower than the rate of 40% projected from a prospective
observational study of similar patients carried out from 1992–1997. The lower stroke risk
observed in COSS for the nonsurgical group is similar to the better outcomes observed in
more recent studies of patients with medically treated asymptomatic carotid artery stenosis,
ascribed to improvements in medical therapy.26 These observations reaffirm the hazard of
using even the most carefully studied historical controls to infer therapeutic efficacy and the
necessity of performing randomized controlled trials to establish clinical benefit. Although
improved hemodynamics in participants who survived EC-IC bypass surgery without
perioperative stroke was associated with low risk of recurrent stroke, the better-than-
expected efficacy of medical therapy in the nonsurgical group was sufficient to nullify any
overall benefit of surgery.
COSS was terminated based on a futility analysis that showed a 29% chance of
demonstrating a statistically significant benefit for surgery if taken to completion, under the
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assumption that the original design effect size was true. The value of 29% was below the
prespecified threshold of 35%. It was later determined that there was an error in the analysis
and that the conditional probability under the assumption of the original design effect size
was 50%. Computing conditional probability requires an assumption about the trends to be
observed in the remainder of the study. Commonly used assumptions are the original design
effect size (as used here for the threshold calculation) or the observed data.27 Use of the
original design effect size assumes that the reminder of the participants enrolled in the trial
will come from a population with the endpoint rates as originally postulated (in this case
24% for the surgical group and 40% for the nonsurgical group). In COSS, the assumption of
the original design effect size was reasonable for the surgical group. The perioperative
stroke rate of 15% in COSS was essentially identical to the rate of 12% from the EC-IC
Bypass Trial. The post-perioperative stoke rate in the COSS surgical group was 6% in two
years (3% per year) as compared to 4% per year for the 385 participants with carotid
occlusion in the surgical group of the EC-IC Bypass Trial.5 These data on the outcome of
surgery are very consistent and it is unlikely that additional participants enrolled in the
surgical arm of COSS would have substantially different overall outcomes. However, given
the rate in the nonsurgical group of 22.7% with an upper 95% confidence bound of 31.6%
observed at the time of the futility analysis, the assumption of the original design effect size
of 40% for calculation of conditional power does not appear to be realistic. Using the
alternative assumption based on the observed rates to calculate conditional power yields a
probability of only 2% that the study would have rejected the null hypothesis if all 372
originally scheduled participants had finished 2-year follow-up. Thus, it is highly unlikely
that COSS would have shown a statistically significant benefit for surgery if taken to
completion.
Interpretation of the study is limited by the relatively small number of outcomes events. The
95% confidence bounds of the difference in the primary endpoint still allow for an absolute
risk difference of 10% in favor of either group. Sham surgery was not performed, so there is
the potential for bias in individual sites reporting potential endpoints for adjudication. This
does not appear to have occurred given that the number of reported events adjudicated not to
be events was 6 in the surgical group and 4 in the nonsurgical group.
The Japanese EC-IC Bypass Trial (JET) was similar in design to COSS. JET used the
combination of reduced baseline cerebral blood flow and reduced cerebral blood flow
increase in response to the vasodilator acetazolamide to identify patients with hemodynamic
cerebral ischemia. From 1998–2002, 206 patients with major cerebral artery occlusive
disease of the internal carotid artery or middle cerebral artery symptomatic within 3 months
were enrolled. Final results of the 2-year follow-up were due in 2004. A second interim
analysis of data from 196 patients followed through January 2002 reported primary
endpoints in 14/98 medically treated patients and 5/98 surgically treated patients (p=.046 by
Kaplan-Meier analysis). 28,29 Examination of the published Kaplan-Meier curves show no
endpoints within the first month in the surgical group. There is no explicit mention whether
the results include 30 day postoperative morbidity and mortality, but it seems unlikely that
this rate was 0 given that it was 12% in the original EC-IC bypass trial and 15% in COSS.
We are not aware of publication of the final JET results.
COSS confirms the importance of hemodynamic factors in the pathogenesis of recurrent
stroke in patients with symptomatic AICAO and the accuracy of PET measurements of OEF
in identifying patients at high risk for recurrent stroke due to poor collateral circulation. The
23% rate of subsequent stroke at 2 years in these patients on medical therapy is comparable
to that for patients with 70–99% symptomatic carotid stenosis.30 Nevertheless, the results of
COSS showed that EC-IC bypass surgery provided no additional benefit over medical
therapy for preventing recurrent stroke.
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Trial Flow Diagram. The most common reasons recorded for failure of screened participants
to meet clinical eligibility criteria were transient ischemic attack or stroke not in territory of
occluded carotid artery (1597), transient ischemic attack or stroke not within 120 days (485),
language comprehension not intact (283), non-atherosclerotic condition causing carotid
artery occlusion (280), modified Barthel index not ≥ 12/20 (168), unsuitable surgical
candidate (160), no occlusion of 1 internal carotid artery (114), not competent to give
informed consent (110), subsequent surgery planned that might alter cerebral hemodynamics
(105), age not 18–85 (104). For each screened participant, only 1 reason needed to be
provided.
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Kaplan-Meier cumulative failure curves for the intention-to-treat analysis of the primary end
point. The primary endpoint is defined in the footnote to Table 3.
The number of participants who remained event free and available for follow-up evaluation
at each 90 day interval is shown in the appropriate color for each group at the bottom of the
graph.
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Table 1
Baseline Characteristics
Surgical Group Nonsurgical Group P Valuea
Participants, No. 97 98
Age, mean(SD), years 58 (9) 58 (9) .71
Male, No. (%) 69 (71) 61 (62) .22
Race White, No. (%) 88 (91) 92 (94) .65
Hypertension, No. (%) 76 (78) 77 (79) .99
Atrial Fibrillation, No. (%) 1(1) 2(2) .99
Hyperlipidemia, No. (%) 79 (81) 86 (88) .45
Diabetes mellitus, No. (%) 21 (22) 23 (23) .93
Cigarette smoking, No. (%) .86
 Current 33 (34) 37 (38)
 Former 56 (58) 51 (52)
 Never 7 (7) 9 (9)
 Unknown 1 (1) 1 (1)
Previous Myocardial Infarction, No. (%) 11 (11) 14(14) .83
Previous Stroke, No. (%) 44 (45) 35 (36) .34
Entry Event Type, No. (%) .39
 Stroke 52 (54) 62 (63)
 Transient Ischemic Attack 44 (45) 35 (36)
 Unknown 1 (1) 1 (1)
Entry Event Side, No. (%) .20
 Right 54 (56) 45 (46)
 Left 43 (44) 53 (54)
Entry Event to Randomization, mean(SD), days 72 (37) 75 (36) .50
PET Ratio, mean(SD) 1.26 (0.14) 1.26 (0.14) .76
Contralateral Carotid Stenosis (%) .41
 <50% 79 (81) 78 (81)
 50% – 69% 11 (11) 7 (7)
 ≥ 70% 7 (7) 11 (11)
 Unknown 0 2 (2)
Modified Barthel Scale (of 20), mean(SD) 19.3 (1.8) 19.5 (1.4) .66
Modified Rankin Score, mean(SD) 1.4 (1.1) 1.4 (1.1) .63
NIHSS, median(IQR) 1.0 (3.0) 1.0 (3.0) .31
SSQoL (Summary,) mean(SD) 3.7 (0.9) 3.7 (0.8) .78
Systolic Blood Pressure, mean(SD), mm Hg 133 (15) 139 (20) .04
Diastolic Blood Pressure, mean(SD), mm Hg 76 (11) 77 (10) .36
LDL-cholesterol, mean(SD), (mg/dL)* 107 (46) 105 (36) .85
Triglycerides, mean(SD), (mg/dL)* 186 (118) 176 (167) .17
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Surgical Group Nonsurgical Group P Valuea
Hemoglobin A1C, mean(SD), (%)* 6.0(1.0) 6.1 (1.1) .29
Abbrevations: LDL, low density lipoprotein; NIHSS, National Institutes of Health stroke scale; PET, positron emission tomography; SSQoL,
Stroke specific quality of life,.
a
P-values were computed using Fisher exact tests for categorical variables and Wilcoxon Rank Sum statistics for continuous variables.
Focal ischemic symptoms in the territory of the occluded carotid artery were categorized as cerebral transient ischemic attack (<24 hrs duration) or
cerebral infarct (≥24 hours duration). LDL-cholesterol, triglyceride, and hemoglobin A1C values are from the 3-month follow-up visit.
The modified Barthel scale (0–20) evaluates the degree of independence in day-to-day self care activities; a higher score is better (indicates greater
independence).The modified Rankin Score (0–6) is intended to define the degree of a participant’s functional disability; a lower score is better
(indicates less functional disability).The NIHSS (0–42) is a quantitative neurological examination developed to measure the degree of neurological
deficit due to stroke; a lower score is better (indicates less neurological deficit).The summary SS-QoL (1–4) asks how self-reported overall quality
of life compares to before stroke; a higher score is better (indicates better quality of life).
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Table 2
Medical Therapy at Last Follow-up
Surgical Group Nonsurgical Group P Valuea
Participants, No. 97 98
Use of anti-thrombotic medication, No. (%) 89/95 (94) 88/94 (94) .99
Systolic Blood Pressure≤ 130 mm Hg, No. (%) 34/76 (45) 29/69 (42) .87
Diastolic Blood Pressure≤ 85 mm Hg, No. (%) 62/76 (82) 48/69 (70) .12
Cigarette smoking (not currently smoking) No. (%) 60/95 (63) 57/92 (62) .79
LDL-cholesterol≤ 100 mg/dL, No. (%) 46/72 (64) 44/62 (71) .46
Triglycerides≤ 150 mg/dL, No. (%) 45/75 (60) 42/64 (66) .60
Hemoglobin A1C≤ 7%, No. (%) 65/74 (88) 53/64 (83) .47
a
P-values from Fisher exact tests. LDL- low density lipoprotein
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